Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + MEDI6383
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**durvalumab + MEDI6383** is a combination of two investigational immuno-oncology agents developed for the treatment of advanced solid tumors. Durvalumab (MEDI4736) is a fully human IgG1κ monoclonal antibody that targets programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to enhance T-cell mediated anti-tumor responses. It acts as an immune checkpoint inhibitor and is approved under the brand name Imfinzi for various cancers. MEDI6383 is an investigational drug evaluated in combination with durvalumab in early-phase clinical trials for recurrent or metastatic solid tumors. The combination aims to leverage complementary mechanisms to stimulate anti-tumor immunity[1][5][7].
- Other names
- durvalumabMEDI-4736MEDI4736MEDI 4736
02
Targets
CD28 (Cluster of Differentiation 28)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + MEDI6383.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + MEDI6383.